Cantor Fitzgerald Predicts Precigen FY2025 Earnings

Precigen, Inc. (NASDAQ:PGEN) – Stock analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for Precigen in a research report issued on Thursday, March 20th. Cantor Fitzgerald analyst J. Kim anticipates that the biotechnology company will post earnings of ($0.27) per share for the year. The consensus estimate for Precigen’s current full-year earnings is ($0.32) per share.

A number of other research firms have also recently commented on PGEN. HC Wainwright reiterated a “buy” rating and set a $6.00 target price on shares of Precigen in a research report on Thursday, March 20th. JMP Securities restated a “market outperform” rating and issued a $5.00 price objective on shares of Precigen in a research note on Tuesday, January 14th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, Precigen presently has a consensus rating of “Moderate Buy” and a consensus target price of $7.00.

Precigen Trading Up 0.6 %

Shares of Precigen stock opened at $1.82 on Monday. The company has a fifty day simple moving average of $1.62 and a 200-day simple moving average of $1.16. Precigen has a 12-month low of $0.65 and a 12-month high of $2.17. The stock has a market cap of $535.16 million, a price-to-earnings ratio of -3.31 and a beta of 1.58.

Precigen (NASDAQ:PGEN) last posted its earnings results on Wednesday, March 19th. The biotechnology company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.02. The firm had revenue of $1.19 million during the quarter, compared to analysts’ expectations of $1.30 million. Precigen had a negative return on equity of 123.06% and a negative net margin of 3,521.68%.

Institutional Investors Weigh In On Precigen

A number of institutional investors have recently added to or reduced their stakes in PGEN. Iridian Asset Management LLC CT lifted its holdings in shares of Precigen by 38.8% in the 4th quarter. Iridian Asset Management LLC CT now owns 5,241,922 shares of the biotechnology company’s stock valued at $5,871,000 after buying an additional 1,465,962 shares during the period. Geode Capital Management LLC grew its stake in shares of Precigen by 1.6% during the 4th quarter. Geode Capital Management LLC now owns 3,299,851 shares of the biotechnology company’s stock worth $3,696,000 after purchasing an additional 53,343 shares during the period. State Street Corp increased its holdings in shares of Precigen by 1.0% in the 3rd quarter. State Street Corp now owns 2,872,064 shares of the biotechnology company’s stock valued at $2,720,000 after purchasing an additional 29,253 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Precigen by 4.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,278,862 shares of the biotechnology company’s stock valued at $1,432,000 after purchasing an additional 56,012 shares during the period. Finally, Northern Trust Corp boosted its holdings in Precigen by 11.6% during the fourth quarter. Northern Trust Corp now owns 1,168,689 shares of the biotechnology company’s stock worth $1,309,000 after buying an additional 121,700 shares in the last quarter. Hedge funds and other institutional investors own 33.51% of the company’s stock.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.